Goldman Sachs Downgrades Cytokinetics to Neutral, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has downgraded Cytokinetics (NASDAQ:CYTK) from Buy to Neutral and lowered the price target from $85 to $60.
August 13, 2024 | 9:13 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has downgraded Cytokinetics from Buy to Neutral and reduced the price target from $85 to $60, indicating a less optimistic outlook.
The downgrade from Buy to Neutral and the significant reduction in the price target from $85 to $60 by a major financial institution like Goldman Sachs is likely to negatively impact investor sentiment and the stock price of Cytokinetics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100